The settlement is conditioned upon approval by all of the litigating states and territories. The only remaining antitrust claims against Sandoz in the US generic antitrust litigation are those brought by individual plaintiffs who opted out of class settlements. Sandoz and Fougera Pharmaceuticals were first named alongside other generic manufacturers in claims alleging that they coordinated prices and allocated customers for certain medicines in the US market. Sandoz says the settlements underscore the company's commitment to integrity, sound governance, and resolving allegations of legacy conduct. Closing out a decade of antitrust liability gives Sandoz one fewer distraction as it navigates an increasingly complex US market environment.